177 related articles for article (PubMed ID: 24372978)
1. Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.
Schlessinger J; Dover JS; Joseph J; Monheit G; Nelson DB; Albright CD; Axford-Gatley RA; Cohen JL;
Dermatol Surg; 2014 Feb; 40(2):176-83. PubMed ID: 24372978
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
Moy R; Maas C; Monheit G; Huber MB;
Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
[TBL] [Abstract][Full Text] [Related]
4. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Baumann L; Brandt FS; Kane MA; Donofrio LM
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
[TBL] [Abstract][Full Text] [Related]
5. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Rubin M; Dover J; Maas C; Nestor M
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Cohen JL; Schlessinger J; Cox SE; Lin X;
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S43-9. PubMed ID: 19945004
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
Rubin MG; Dover J; Glogau RG; Goldberg DJ; Goldman MP; Schlessinger J
J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
9. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
[TBL] [Abstract][Full Text] [Related]
11. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
Beer KR; Julius H; Dunn M; Wilson F
J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.
Monheit GD; Baumann L; Maas C; Rand R; Down R
Dermatol Surg; 2020 Jan; 46(1):61-69. PubMed ID: 31356432
[TBL] [Abstract][Full Text] [Related]
13. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.
Nettar KD; Yu KC; Bapna S; Boscardin J; Maas CS
Arch Facial Plast Surg; 2011; 13(6):380-6. PubMed ID: 21690460
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of incobotulinumtoxin A for the correction of glabellar lines among patients with skin types IV to VI.
Jackson BA; Vogel MR
J Drugs Dermatol; 2015 Apr; 14(4):350-3. PubMed ID: 25844607
[TBL] [Abstract][Full Text] [Related]
15. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
16. A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study.
Green JB; Mariwalla K; Coleman K; Ablon G; Weinkle SH; Gallagher CJ; Vitarella D; Rubio RG
Dermatol Surg; 2021 Jan; 47(1):42-46. PubMed ID: 32773447
[TBL] [Abstract][Full Text] [Related]
17. Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study.
Kestemont P; Hilton S; Andriopoulos B; Prygova I; Thompson C; Volteau M; Ascher B
Aesthet Surg J; 2022 Feb; 42(3):301-313. PubMed ID: 34472596
[TBL] [Abstract][Full Text] [Related]
18. A Prospective, Neurophysiologic Comparative Study to Assess the Efficacy and Duration of Effect of IncobotulinumtoxinA and AbobotulinumtoxinA in the Treatment of Crow's Feet.
Saybel A; Artemenko A; Nikitin S; Kurenkov A
J Drugs Dermatol; 2015 Nov; 14(11):1291-6. PubMed ID: 26580879
[TBL] [Abstract][Full Text] [Related]
19. AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study.
Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Dayan S; Berg AK; Munavalli G
J Drugs Dermatol; 2021 Sep; 20(9):980-987. PubMed ID: 34491016
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
Monheit GD; Cohen JL;
J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
